Drug Details

General Information of the Drug (ID: DR1567)
Name
Terazosin
Synonyms
terazosin; Terazosine; 63590-64-7; Hytrin; Terazosina; Terazosinum; Flumarc; Fosfomic; Vasomet; Blavin; Terazosine [INN-French]; Terazosinum [INN-Latin]; Terazosina [INN-Spanish]; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine; CHEMBL611; MLS000069703; Abbott-45975; CHEBI:9445; Terazosin (hydrochloride); [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone; SMR000058309; Terazosin [INN:BAN]; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine; 6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine; (4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(tetrahydrofuran-2-yl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone; 6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; Abbott 45975; 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine; Terazosabb (TN); Terazosin (INN); 141269-45-6; MFCD00467965; 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)4-[(tetrahydro-2-furanyl)carbonyl]piperazine; terazosin a; terazosinhydrochloride; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)4-[(tetrahydro-2-furanyl)carbonyl]piperazine hydrochloride; Opera_ID_1910; Prestwick0_000751; Prestwick1_000751; Prestwick2_000751; Prestwick3_000751; 141269-44-5; SCHEMBL6528; Lopac0_001138; REGID_for_CID_5401; BSPBio_000762; MLS001201836; MLS006011889; SPBio_002701; BPBio1_000840; GTPL7302; MET029; DTXSID3023639; HMS2090P21; HMS2232N21; HMS3259F04; HMS3369P14; HMS3371E20; HMS3742I09; 109351-34-0; HY-B0371; 4097AH; BBL010743; BDBM50033111; STK567029; AKOS005266642; CCG-205212; DB01162; MCULE-4030111564; NC00689; SDCCGSBI-0051105.P002; VA11839; 6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)-; NCGC00016026-04; NCGC00016026-05; NCGC00016026-08; NCGC00016026-11; NCGC00025191-03; AC-11120; H963; LS-14728; FT-0630739; C07127; D08569; 590T647; L000692; Q280786; BRD-A22256192-003-03-7; BRD-A22256192-003-14-4; Z1172269406; 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine; 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)-piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-{(tetnaphydro-2-furanyl)carbonyl}piperazine; 6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]-3,4-dihydroquinazolin-4-imine; 6,7-Dimethoxy-2-[4-(tetrahydro-2-furanylcarbonyl)-1-piperazinyl]-4-quinazolinamine #; 6,7-dimethoxy-2-{4-[(oxolan-2-yl)carbonyl]piperazin-1-yl}quinazolin-4-amine; Methanone, [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl](tetrahydro-2-furanyl)-; 1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-4-[[(2RS)-2,3,4,5-tetrahydrofuran-2-yl]carbonyl]piperazine
    Click to Show/Hide
Molecular Type
Small molecule
Disease Prostate hyperplasia [ICD-11: GA90] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C19H25N5O4
PubChem CID
5401
Canonical SMILES
COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC
InChI
1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)
InChIKey
VCKUSRYTPJJLNI-UHFFFAOYSA-N
CAS Number
CAS 63590-64-7
ChEBI ID
CHEBI:9445
TTD Drug ID
D0P9RF
DrugBank ID
DB01162
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Genistein      Glycine max     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression BCL-xL  Molecule Info 
Pathway MAP
Down-regulation Expression NRP1  Molecule Info 
Pathway MAP
                    In-vitro Model DU145 CVCL_0105 Prostate carcinoma Homo sapiens
                    Experimental
                    Result(s)		 The terazosin/genistein combination was more effective in inhibiting cell growth and VEGF expression as well as inducing apoptosis of the metastatic, androgen-independent prostate cancer cell line, DU-145, than either alone.
Target and Pathway
Target(s) Adrenergic receptor alpha-1D (ADRA1D)  Molecule Info  [3]
KEGG Pathway Calcium signaling pathway Click to Show/Hide
2 cGMP-PKG signaling pathway
3 Neuroactive ligand-receptor interaction
4 Adrenergic signaling in cardiomyocytes
5 Vascular smooth muscle contraction
6 Salivary secretion
NetPath Pathway IL2 Signaling Pathway Click to Show/Hide
Reactome Adrenoceptors Click to Show/Hide
2 G alpha (q) signalling events
3 G alpha (12/13) signalling events
WikiPathways Monoamine GPCRs Click to Show/Hide
2 Calcium Regulation in the Cardiac Cell
3 GPCRs, Class A Rhodopsin-like
4 Gastrin-CREB signalling pathway via PKC and MAPK
5 GPCR ligand binding
6 GPCR downstream signaling
7 GPCRs, Other
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7302).
Reference 2 Combined effects of terazosin and genistein on a metastatic, hormone-independent human prostate cancer cell line. Cancer Lett. 2009 Apr 8;276(1):14-20.
Reference 3 Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link